MedTrace Logo

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

NCT02413450 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-01-16

No results posted yet for this study

Summary

Human induced pluripotent stem cells (hiPSCs) have driven a paradigm shift in the modeling of human disease; the ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and phenotypic variability, with applications in personalized predictive pharmacology/toxicology, cell therapy and regenerative medicine. This research will collect blood or skin biopsies from patients and healthy controls for the purpose of generating cell and tissue models of Mendelian heritable forms of heart disease focusing on cardiomyopathies, channelopathies and neuromuscular diseases. Cardiomyocytes derived from hiPSCs will provide a ready source of disease specific cells to study pathogenesis and therapeutics.

Conditions

  • Inherited Cardiac Arrythmias
  • Long QT Syndrome (LQTS)
  • Brugada Syndrome (BrS)
  • Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
  • Early Repolarization Syndrome (ERS)
  • Arrhythmogenic Cardiomyopathy (AC, ARVD/C)
  • Hypertrophic Cardiomyopathy (HCM)
  • Dilated Cardiomyopathy (DCM)
  • Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
  • Normal Control Subjects

Sponsors & Collaborators

Principal Investigators

  • Andreas Barth, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2030-08-31
Completion
2031-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02413450 on ClinicalTrials.gov